Large cap pharmaceuticals sector company Cipla Ltd today issued fresh acquisition update on investment in Medpro South Africa Proprietary Limited after market hours. Last trading price of the pharma giant shares on Bombay Stock Exchange stood at Rs 1482.20 per share with intraday gain of 0.61%. The stock witnessed surge of 2.31% in last two weeks in a weak market when BSE Sensex fell 3.33% during this time period. The market capitalisation of the company stood at Rs 1,19,704.55 crore and return on equity (ROE) is 16.17%. Check key details below:
Cipla Ltd Issues Acquisition Update
According to the BSE filing of the company dated February 18, 2025, “In compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 3rd February 2025, we hereby notify that the Company has completed investment of approx. ZAR 900 million in Cipla Medpro South Africa Proprietary Limited, South Africa, wholly owned subsidiary against allotment of 40,742,417 shares on 18th February 2025.”
Cipla Ltd Q3 Results
The consolidated net profit of the leading drugmaker surged 49% to Rs 1,571 crore for the December 2024 quarter as against Rs 1056 crore declared in the corresponding quarter of last year. The company’s Q3DY25 revenue from operations surged 7% to Rs 7073 crore as compared to Rs 6,604 crore announced in the similar quarter of last year. Its EBITDA zoomed by 14% year-on-year (YoY) to Rs 1989 crore for the quarter ended December 2024. Meanwhile, EBITDA margin for the quarter under review expanded by 200 basis points to 28% from 26% reported last year.
Cipla Shares Performance
The 52-week high price of Cipla shares on BSE stood at Rs 1702.00 per share (as on 09/10/2024) and 52-week low price is Rs 1317.60 per share (as on 10/05/2024), respectively. Shares of Cipla gained 2.76% in last 1-month, slumped 3.18% year-to-date, and rose 2.92% in last 1-year. In last 2-years, Cipla stock recorded surge of 44.49% and gave returns of 240.23% in last 5-years.
Should You Buy Cipla Shares Post Q3 Results
According to leading brokerage firm Prabhudas Lilladher, “our FY26E/27E EPS stands marginally increased by 1-3%. At CMP, stock is trading 22x FY26E EPS. We maintain our ‘BUY’ with TP of Rs1,730/share. Timely launch of critical high-value products in the US in FY26E/27E will be key.”
Meanwhile, Nuvama has “Hold” rating on the pharma stock. The brokerage recommended a target price of Rs 1,620 upgraded from the earlier target price of 1,601 at 26 times FY27 earning per share (EPS). On the other hand, global brokerages HSBC and Nomura are upbeat on Cipla, and assigned “Buy” on the stock with the target price of Rs Rs 1800 and Rs 1780, respectively.
Cipla Dividend History
Cipla recommended a total of 24 dividends since August 22, 2003. In last 1-year, Cipla recommended an equity dividend amounting to Rs 13.00 per share. At the current share price of Rs 1482.20, it offers a dividend yield of 0.88%.
Cipla Bonus Share History
It recommended bonus share once since April 24, 2006. It last bonus was declared in the ratio 3:2 with ex-date of April 24, 2006, according to Trendlyne.
Disclaimer: The stock has been picked from the brokerage report of Nomura, HSBC, Nuvama, and Prabhudas Lilladher. Moneydaily.in, the author, and the respective brokerage house will not be held accountable for any losses caused as a result of decisions based on the article. Moneydaily.in advises readers to do their own research or consult a SEBI registered investment advisor before making any investment decisions.
Recommended: Order Book At Rs 18,000 Cr: LIC, FII-Backed Metal Stock Bags Rs 3000 Cr Orders
Leave a Reply